Plans to build a long-promised biological manufacturing facility in Manhattan have fizzled, though company leaders prefer not ...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

The recently implemented measures include the divestiture of certain non-core assets and the initiation of programs designed to optimize operational efficien Agreement reinforces Scorpius' position as ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a groundbreaking advancement that addresses ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a groundbreaking advancement ...

(“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annual ...

Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO") ...

Both companies are also exploring a potential commercial-scale manufacturing agreement, reinforcing Scorpius's role as a reliable biomanufacturing partner. KaloCyte is advancing towards clinical ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a ...